Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 446

Sort by

Sort Order Select

Journal Articles

Rapcabtagene autoleucel (YTB323) for patients with first line high-risk large B-cell lymphoma: Phase II interim results

Blood (2025) 146 (Supplement 1): 670.

https://doi.org/10.1182/blood-2025-670

Published: 2025

Journal Articles

Young (35 years) matched sibling donors for allogeneic transplantation with post-transplantation cyclophosphamide in patients with secondary acute myeloid leukemia in first complete remission: A study from the ALWP/EBMT

Blood (2025) 146 (Supplement 1): 4193.

https://doi.org/10.1182/blood-2025-4193

Published: 2025

Journal Articles

Allogenic donor-derived cytokine-induced killer (CIK) cells as a safe post-transplant treatment for disease recurrence in the setting of HLA-mismatched donors

Blood (2025) 146 (Supplement 1): 4154.

https://doi.org/10.1182/blood-2025-4154

Published: 2025

Journal Articles

Trial in progress: Efficacy and safety of givinostat versus hydroxyurea in patients with polycythemia vera (GIV-IN-PV)

Alessandro Rambaldi, John Mascarenhas, Paolo Bettica, Maurizio Caserini, Javier Suarez-Almarza, Lucia Zanetta, Alessandro Vannucchi

Blood (2025) 146 (Supplement 1): 3828.

https://doi.org/10.1182/blood-2025-3828

Published: 2025

Journal Articles

Phase 1 evaluation of the safety and efficacy of rapcabtagene autoleucel (YTB323) in adult patients with Relapsed/Refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)

Blood (2025) 146 (Supplement 1): 811.

https://doi.org/10.1182/blood-2025-811

Published: 2025

Journal Articles

VYSION (VYxeoS liposomal® Italian Observational study iN the real practice): Study design and baseline characteristics

Livio Pagano, Alessandra Sperotto, Elisabetta Todisco, Roberto Lemoli, Massimo Breccia, Alessandro Rambaldi, Sara Galimberti, Saemi Park, Giovanna Dinelli, Rafaella Gentilella, Adriano Venditti

Blood (2025) 146 (Supplement 1): 5212.

https://doi.org/10.1182/blood-2025-5212

Published: 2025

Journal Articles

First results of the Phase III GIMEMA ALL2820 trial comparing ponatinib plus blinatumomab to imatinib and chemotherapy for newly diagnosed adult ph+ acute lymphoblastic leukemia patients

Sabina Chiaretti, Mariangela Di Trani, Cristina Skert, Loredana Elia, Giada Almici, Irene Della Starza, Deborah Cardinali, Vittorio Bellomarino, Stefano Soddu, Monica Messina, Martina Rachele Marino, Maria Stefania De Propris, Erika Borlenghi, Francesco Di Raimondo, Michela Ansuinelli, Caterina Alati, Daniele G. Mattei, Valentina Mancini, Patrizia Chiusolo, Barbara Scappini, Maria Paola Martelli, Prassede Salutari, Marco Cerrano, Bianca Serio, Antonella Cucca, Mario Luppi, Daniele Vallisa, Crescenza Pasciolla, Claudio Romani, Martina Chiarucci, Federico Mosna, Massimiliano Bonifacio, Nicola Stefano Fracchiolla, Monica Bocchia, Silvia Imbergamo, Catello Califano, Giuseppe Rodolfo Nunziata, Mario Annunziata, Antonino Mule', Patrizia Zappasodi, Fabio Giglio, Daniela Pietrasanta, Matteo Della Porta, Maurizio Musso, Monia Lunghi, Francesco Zaja, Elisabetta Todisco, Claudia Maria Basilico, Alfonso Piciocchi, Paola Fazi, Alessandro Rambaldi, Robin Foà

Blood (2025) 146 (Supplement 1): 439.

https://doi.org/10.1182/blood-2025-439

Published: 2025

Journal Articles

An integrative prognostic model for transplant outcomes in myelofibrosis

Blood (2025) 146 (Supplement 1): 912.

https://doi.org/10.1182/blood-2025-912

Published: 2025

Journal Articles

Matched unrelated vs. Haploidentical donor for allogeneic stem cell transplantation in patients with acute leukemia with identical GvHD prophylaxis – a randomized prospective european trial.

Blood (2025) 146 (Supplement 1): 171.

https://doi.org/10.1182/blood-2025-171

Published: 2025

Journal Articles

Bone marrow adipocytes (BMA) as a novel biomarker of molecular response in patients with essential thrombocythemia (ET) and polycythemia vera (PV) treated with pegylated interferon alfa-2A

John Mascarenhas, Justin Johnson, Heidi Kosiorek, Megan Metzger, Tiziano Barbui, Josef Prchal, Alessandro Rambaldi, Abdulraheem Yacoub, Ashley Yu, Ruben Mesa, Marina Kremyanskaya, Amylou Dueck, Ronald Hoffman, Mohamed Salama

Blood (2025) 146 (Supplement 1): 5590.

https://doi.org/10.1182/blood-2025-5590

Published: 2025

Journal Articles

Ropeginterferon alfa-2b in 248 patients with polycythemia vera: Results from the italian cohort of a prospective, non-interventional, post-authorization study (ROPEG-PV)

Blood (2025) 146 (Supplement 1): 5572.

https://doi.org/10.1182/blood-2025-5572

Published: 2025

Journal Articles

A novel multi-target NGS application for molecular monitoring of measurable residual disease in Acute Myeloid Leukemia

Annalisa Condorelli, Chiara Pavoni, Federico Lussana, Anna Grassi, Marco Frigeni, Orietta Spinelli, Alessandra Algarotti, Alessandro Rambaldi, Silvia Salmoiraghi

Blood (2025) 146 (Supplement 1): 3513.

https://doi.org/10.1182/blood-2025-3513

Published: 2025

Journal Articles

Radiation-free therapy for the initial treatment of good prognosis early non-bulky HL, defined by a low metabolic tumor volume and a negative interim PET after 2 chemotherapy cycles. a phase II prospective rafting trial

Kateryna Filonenko, Marco Picardi, Michal Kurlapski, Livio Trentin, Eva Domingo Domenech, Caterina Patti, Ramon Garcia-Sanz, Javier Nuñez Cespedes, Javier Lopez Jimenez, Agnieszka Giza, Stephane Chauvie, Davide Rossi, Andrea Riccardo Filippi, Maria Pirosa, Marta Bednarek, Anna Sureda Balarí, Alessandro Rambaldi, Andrea Gallamini, Jan Maciej Zaucha

Blood (2025) 146 (Supplement 1): 8243.

https://doi.org/10.1182/blood-2025-8243

Published: 2025

Journal Articles

Cytomegalovirus (CMV) reactivation negatively impacts survival after CAR T-cell therapy in lymphoma patients: Results from the CART-SIE study

Blood (2025) 146 (Supplement 1): 3722.

https://doi.org/10.1182/blood-2025-3722

Published: 2025

Journal Articles

T cell replete haploidentical transplantation compared to mismatched unrelated allogeneic transplantation with post-transplantation cyclophosphamide in patients with secondary acute myeloid leukemia in first complete remission: A study from the ALWP/EBMT

Blood (2025) 146 (Supplement 1): 114.

https://doi.org/10.1182/blood-2025-114

Published: 2025

Journal Articles

Addition of thiotepa to a busulphan based conditioning regimen does not improve survival in patients allografted for acute myeloid leukaemia and myelodysplasia: Results of the UK impact cosi trial

Blood (2025) 146 (Supplement 1): 110.

https://doi.org/10.1182/blood-2025-110

Published: 2025

Journal Articles

Hbc-positive status for hepatis B virus does not affect CAR-T cell outcomes in lymphoma: Results from the CART-SIE study

Blood (2025) 146 (Supplement 1): 7636.

https://doi.org/10.1182/blood-2025-7636

Published: 2025

Journal Articles

Venetoclax and decitabine in myeloproliferative neoplasm-blast Phase (MPN-BP): Results of enable, a gimema and airc-mynerva multicenter, Phase 2 trial

Blood (2025) 146 (Supplement 1): 1025.

https://doi.org/10.1182/blood-2025-1025

Published: 2025

Journal Articles

Up-front blinatumomab improves MRD clearance and outcome in adult Ph – B-lineage ALL: the GIMEMA LAL2317 phase 2 study

Blood (2025) 145 (21): 2447–2459.

https://doi.org/10.1182/blood.2024027500

Published: 2025

Includes: Supplemental data

Journal Articles

GMALL B ALL/NHL 2002 Protocol Yields High Response Rates and Durable Responses in High-Grade B Cell Lymphoma: A Retrospective, Single-Center Study

Silvia Ferrari, Anna Maria Barbui, Gritti Giuseppe, Andrea Rossi, Anna Grassi, Francesco Ballardini, Monica Rondi, Chiara Pavoni, Paolo Fruscella, Andrea Gianatti, Alessandro Rambaldi

Blood (2024) 144 (Supplement 1): 3114.

https://doi.org/10.1182/blood-2024-208027

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Rapcabtagene autoleucel (YTB323) for patients with first line high-risk large B-cell lymphoma: Phase II interim results

Young (35 years) matched sibling donors for allogeneic transplantation with post-transplantation cyclophosphamide in patients with secondary acute myeloid leukemia in first complete remission: A study from the ALWP/EBMT

Allogenic donor-derived cytokine-induced killer (CIK) cells as a safe post-transplant treatment for disease recurrence in the setting of HLA-mismatched donors

Trial in progress: Efficacy and safety of givinostat versus hydroxyurea in patients with polycythemia vera (GIV-IN-PV)

Phase 1 evaluation of the safety and efficacy of rapcabtagene autoleucel (YTB323) in adult patients with Relapsed/Refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)

VYSION (VYxeoS liposomal® Italian Observational study iN the real practice): Study design and baseline characteristics

First results of the Phase III GIMEMA ALL2820 trial comparing ponatinib plus blinatumomab to imatinib and chemotherapy for newly diagnosed adult ph+ acute lymphoblastic leukemia patients

An integrative prognostic model for transplant outcomes in myelofibrosis

Matched unrelated vs. Haploidentical donor for allogeneic stem cell transplantation in patients with acute leukemia with identical GvHD prophylaxis – a randomized prospective european trial.

Bone marrow adipocytes (BMA) as a novel biomarker of molecular response in patients with essential thrombocythemia (ET) and polycythemia vera (PV) treated with pegylated interferon alfa-2A

Ropeginterferon alfa-2b in 248 patients with polycythemia vera: Results from the italian cohort of a prospective, non-interventional, post-authorization study (ROPEG-PV)

A novel multi-target NGS application for molecular monitoring of measurable residual disease in Acute Myeloid Leukemia

Radiation-free therapy for the initial treatment of good prognosis early non-bulky HL, defined by a low metabolic tumor volume and a negative interim PET after 2 chemotherapy cycles. a phase II prospective rafting trial

Cytomegalovirus (CMV) reactivation negatively impacts survival after CAR T-cell therapy in lymphoma patients: Results from the CART-SIE study

T cell replete haploidentical transplantation compared to mismatched unrelated allogeneic transplantation with post-transplantation cyclophosphamide in patients with secondary acute myeloid leukemia in first complete remission: A study from the ALWP/EBMT

Addition of thiotepa to a busulphan based conditioning regimen does not improve survival in patients allografted for acute myeloid leukaemia and myelodysplasia: Results of the UK impact cosi trial

Hbc-positive status for hepatis B virus does not affect CAR-T cell outcomes in lymphoma: Results from the CART-SIE study

Venetoclax and decitabine in myeloproliferative neoplasm-blast Phase (MPN-BP): Results of enable, a gimema and airc-mynerva multicenter, Phase 2 trial

Up-front blinatumomab improves MRD clearance and outcome in adult Ph – B-lineage ALL: the GIMEMA LAL2317 phase 2 study

GMALL B ALL/NHL 2002 Protocol Yields High Response Rates and Durable Responses in High-Grade B Cell Lymphoma: A Retrospective, Single-Center Study

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only